S1PR3 inhibitors may also be beneficial for treating other inflammatory disorders where S1PR3-expressing somatosensory neurons have been shown to contribute to neurogenic inflammation, such as asthma (Tränkner et al., 2014). This evidence concerns the gene S1PR3 and asthma.